AstraZeneca, Daiichi’s trastuzumab ADC sets new efficacy bar in breast cancer

Trastuzumab deruxtecan from AstraZeneca and Daiichi Sankyo may have established a new threshold for efficacy in HER2+ breast cancer based on pivotal Phase II data.

The data were better, in a sicker patient population, than what ADC Kadcyla ado-trastuzumab emtansine demonstrated in the Phase III EMILIA trial in the second-line setting...